Edwards EVOQUE Eos MISCEND Study
← catalyst calendarNCT02718001 · readout in 620 d
Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
123estimated
Sites
19
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2015-02-06 | actual | When the study began enrolling |
| Primary completion | 2028-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2016-03-24 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mitral Valve Regurgitation (Degenerative or Functional)
Intervention
- Device: Edwards EVOQUE Eos Mitral Valve Replacement System — also filed as CardiAQ-Edwards™ Transcatheter Mitral Valve (TMV), Edwards FORTIS™ Transcatheter Mitral Valve (TMV), Transcatheter Mitral Valve Replacement (TMVR), Edwards EVOQUE Transcatheter Mitral Valve Replacement System
Primary outcome
what the primary-completion date above is the date OFComposite of major adverse events
measured 30 days
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed